학술논문
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
Document Type
Article
Author
Source
In Clinical Lung Cancer May 2024
Subject
Language
ISSN
1525-7304